TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26702121

Group type: EXPERIMENTAL
Intervention: 2000 IU daily oral vitamin D3 supplementation
Number of subjects: 75

Group type: COMPARATOR
Intervention: 1000 IU daily oral vitamin D3 supplementation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 24915941

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 20
Study: 22054213

Group type: EXPERIMENTAL
Intervention: Aneurysm clipping
Number of subjects: 500

Group type: COMPARATOR
Intervention: Endovascular coil embolization
Number of subjects: 500
Study: 21156112

Group type: EXPERIMENTAL
Intervention: Grøn Tuborg
Number of subjects: 57

Group type: COMPARATOR
Intervention: Ceres Royal Pilsner
Number of subjects: 57
Study: 18206031

Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 129

Group type: COMPARATOR
Intervention: Normotensive patients
Number of subjects: 129
Study: 15845315

Group type: EXPERIMENTAL
Intervention: Standard Cognitive Behavioral Therapy (CBT)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Combined Cognitive Behavioral Therapy and Contingency Management (CBT+CM)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Culturally Tailored Cognitive Behavioral Therapy (GCBT)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Overall (all treatments)
Number of subjects: 162
Study: 12821551

Group type: EXPERIMENTAL
Intervention: Electrophysiologically (EP)‐guided therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No EP‐guided therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EP-guided therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No EP-guided therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serial EP-guided drug testing
Number of subjects: 0
Study: 10382127

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) triple therapy
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth pectin (CBP) triple therapy
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: CBS quadruple therapy
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: CBP quadruple therapy
Number of subjects: 205
Study: 8916625

Group type: EXPERIMENTAL
Intervention: Behavioral couples therapy (BCT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No-couples-treatment control group
Number of subjects: 80
Study: 1919540

Group type: EXPERIMENTAL
Intervention: recombinant human interferon‐gamma (rIFN gamma) 0.1 mg/m2 intramuscularly thrice weekly for 16 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: no anti‐viral therapy (controls)
Number of subjects: 19
Study: 6804900

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Norethisterone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31033141

Group type: EXPERIMENTAL
Intervention: Wilms' tumor 1 peptide‐loaded dendritic cells (DCs) and OK‐432 adjuvant combined with conventional chemotherapy
Number of subjects: 11
Study: 28872993

Group type: EXPERIMENTAL
Intervention: Group I (complete removal of hypomineralized tissue)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Group II (removal of carious and cheesy hypomineralized tissue)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Group III (removal of hypomineralized tissue with deproteinization)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Group IV (control group, unaffected carious PFMs)
Number of subjects: 126
Study: 25793967

Group type: EXPERIMENTAL
Intervention: Integrative health care (IHC) team collaboration during consensus case conferences
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Discourse analysis of IHC team interactions
Number of subjects: 26
Study: 21712700

Group type: EXPERIMENTAL
Intervention: Pirfenidone (PFD) 1800 mg/day for 6 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Capsulectomy (control group)
Number of subjects: 34
Study: 21187258

Group type: EXPERIMENTAL
Intervention: Traditional HF management guided by hemodynamic information from the CardioMEMS HF sensor
Number of subjects: 550

Group type: COMPARATOR
Intervention: Traditional HF disease management
Number of subjects: 550
Study: 19215685

Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg midazolam
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg midazolam
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 45
Study: 17123214

Group type: EXPERIMENTAL
Intervention: Multidisciplinary in‐patient treatment programme
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Multidisciplinary functional restoration treatment for patients with high risk of chronification
Number of subjects: 483

Group type: COMPARATOR
Intervention: Control group with standard rehabilitation programme
Number of subjects: 483
Study: 15518605

Group type: EXPERIMENTAL
Intervention: Preoperative coronary revascularization recommendations by cardiologists
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Preferred method of revascularization
Number of subjects: 12
Study: 11573589

Group type: EXPERIMENTAL
Intervention: Amino acid enriched solution (AMIPAREN) infusion at a rate of 166 kJ h(‐1) in AA-PTC group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amino acid enriched solution (AMIPAREN) infusion at a rate of 166 kJ h(‐1) in AA-TOF group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amino acid enriched solution (AMIPAREN) infusion in AA-PTC group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amino acid enriched solution (AMIPAREN) infusion in AA-TOF group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline in C-PTC group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline in C-TOF group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline in C-PTC and C-TOF groups
Number of subjects: 60
Study: 9028489

Group type: EXPERIMENTAL
Intervention: Cuprophan membrane
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile membrane
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All methods of Kt/V‐urea calculation
Number of subjects: 8
Study: 8332615

Group type: EXPERIMENTAL
Intervention: High dose cocaine (2 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low dose cocaine (1 mg/kg)
Number of subjects: 30
Study: 3511017

Group type: EXPERIMENTAL
Intervention: Vitamins supplemented with iron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamins alone
Number of subjects: 0
Study: 30355189

Group type: EXPERIMENTAL
Intervention: Active VNS
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control VNS
Number of subjects: 17
Study: 27196998

Group type: EXPERIMENTAL
Intervention: Pre-hospital ticagrelor 180 mg loading dose
Number of subjects: 37

Group type: COMPARATOR
Intervention: In-hospital ticagrelor 180 mg loading dose
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Morphine administration
Number of subjects: 37
Study: 25300611

Group type: EXPERIMENTAL
Intervention: Neuroendoscopy group
Number of subjects: 2448

Group type: EXPERIMENTAL
Intervention: Stereotactic aspiration group
Number of subjects: 2448

Group type: COMPARATOR
Intervention: Craniotomy group
Number of subjects: 2448

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 2448
Study: 22965994

Group type: EXPERIMENTAL
Intervention: Autologous c-kit(+) cardiac stem cells (CSCs)
Number of subjects: 33
Study: 21215151

Group type: EXPERIMENTAL
Intervention: Intra-aortic vacant guide wire
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional treatment (group A)
Number of subjects: 86
Study: 18251358

Group type: EXPERIMENTAL
Intervention: Vaginal estradiol cream
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 10
Study: 16545642

Group type: EXPERIMENTAL
Intervention: MSCT (multislice computed tomography)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Palpography
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional invasive coronary imaging (quantitative coronary angiography and IVUS)
Number of subjects: 67
Study: 12845387

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (GB) therapy, 80 mg three times daily
Number of subjects: 8
Study: 10980877

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study: 8623871

Group type: EXPERIMENTAL
Intervention: Nonclosure of the visceral peritoneum
Number of subjects: 549

Group type: COMPARATOR
Intervention: Closure of the visceral peritoneum
Number of subjects: 549
Study: 1458890

Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 180

Group type: COMPARATOR
Intervention: 1 mg gemeprost as a vaginal pessary
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Treatment in the sitting-room
Number of subjects: 180

Group type: COMPARATOR
Intervention: Treatment in the ward
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Overall satisfaction with method of treatment
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Recommendation of method to friends
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Preference for partner or friend presence
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Preference to stay in hospital after administration of prostaglandin
Number of subjects: 180
Study: 3917698

Group type: EXPERIMENTAL
Intervention: Catheter removal and later replacement
Number of subjects: 113

Group type: COMPARATOR
Intervention: Replacement over a guidewire
Number of subjects: 113

Group type: COMPARATOR
Intervention: Guidewire procedure
Number of subjects: 113
Study: 31173939

Group type: EXPERIMENTAL
Intervention: HT with bilateral annexectomy or ovarian conservation using 3-mm instruments (group A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional 5-mm instruments (group B)
Number of subjects: 32
Study: 29633139

Group type: EXPERIMENTAL
Intervention: Study-enhanced PRO completion rates (web-based PHR, IVR calls, live outreach)
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: PRO completion at 3 months
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Response by method of PRO administration
Number of subjects: 831
Study: 27511452

Group type: EXPERIMENTAL
Intervention: Testosterone (T) administration
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 117
Study: 25686811

Group type: EXPERIMENTAL
Intervention: Telemedicine-based collaborative care (TBCC)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Practice-based collaborative care (PBCC)
Number of subjects: 364
Study: 23489530

Group type: EXPERIMENTAL
Intervention: Insulin resistance (HOMA >1.24)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Insulin resistance (HOMA <1.24)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Baseline LVH (present)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Baseline LVH (not present)
Number of subjects: 250
Study: 19947900

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily
Number of subjects: 166

Group type: COMPARATOR
Intervention: Diclofenac sodium as needed (Control)
Number of subjects: 166
Study: 18155331

Group type: EXPERIMENTAL
Intervention: Levodopa (ON)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Parkinson's disease (OFF)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 16166441

Group type: EXPERIMENTAL
Intervention: 2-methoxyestradiol 1,200 mg/d
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 2-methoxyestradiol 400 mg/d
Number of subjects: 33
Study: 15709726

Group type: EXPERIMENTAL
Intervention: STA-MCA anastomosis combined with best medical therapy
Number of subjects: 930

Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: STA-MCA anastomosis
Number of subjects: 930
Study: 10588962

Group type: EXPERIMENTAL
Intervention: Immediate antiandrogen therapy (goserelin or bilateral orchiectomy)
Number of subjects: 98
Study: 8759655

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d.
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg/day
Number of subjects: 88
Study: 1868960

Group type: EXPERIMENTAL
Intervention: Premixture 3/7 (Actraphane HM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Extemporary mixtures of regular + NPH at mixing ratios from 2/8 to 4/6
Number of subjects: 20
Study: 6275706

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (Premarin) and medrogestone (Colpro)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Clonidine (Dixarit)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (10 asymptomatic postmenopausal women)
Number of subjects: 23
Study: 30576544

Group type: EXPERIMENTAL
Intervention: Netupitant 30 mg
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Netupitant 100 mg
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Netupitant 300 mg
Number of subjects: 402
Study: 29759434

Group type: EXPERIMENTAL
Intervention: Repeat electrophysiology study after 2 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80
Study: 26511056

Group type: EXPERIMENTAL
Intervention: Bone marrow derived mononuclear cell (BMMNC) administration
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 25052076

Group type: EXPERIMENTAL
Intervention: Automated tube voltage selection (ATVS)
Number of subjects: 72
Study: 21905001

Group type: EXPERIMENTAL
Intervention: Ocrelizumab 200 mg
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: Ocrelizumab 500 mg
Number of subjects: 986

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 986
Study: 19678774

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba L. tablets (40 mg leaf extracts), taken three times a day from the 16th day of the menstrual cycle to the 5th day of the next cycle.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo, taken three times a day from the 16th day of the menstrual cycle to the 5th day of the next cycle.
Number of subjects: 90
Study: 17183512

Group type: EXPERIMENTAL
Intervention: Multidisciplinary structured home training programme, ergonomic advice, wrist and/or night bandages as necessary.
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Multidisciplinary structured home training programme.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group received conventional treatment (corticosteroid injections, stretching, or no intervention).
Number of subjects: 78
Study: 15334379

Group type: EXPERIMENTAL
Intervention: Pancreas Tonic (2 capsules 3 times a day) for 3 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pancreas Tonic
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pancreas Tonic and Placebo
Number of subjects: 36
Study: 12015475

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 0
Study: 11801985

Group type: EXPERIMENTAL
Intervention: Acellular dermis placement during superficial lobe parotidectomy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Superficial lobe parotidectomy without acellular dermis
Number of subjects: 64
Study: 9274439

Group type: EXPERIMENTAL
Intervention: exemestane 0.5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: exemestane 1 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: exemestane 2.5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: exemestane 5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: exemestane (all doses)
Number of subjects: 20
Study: 7686279

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion (mode A)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Continuous basal rate subcutaneous infusion + PCA (mode B)
Number of subjects: 8
Study: 3530126

Group type: EXPERIMENTAL
Intervention: Ceftazidime-Vancomycin (CV)
Number of subjects: 79

Group type: COMPARATOR
Intervention: KGC (Ceftazidime, Cephalothin, Gentamicin, Carbenicillin)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Ceftazidime alone
Number of subjects: 79
Study: 29785872

Group type: EXPERIMENTAL
Intervention: Bedside fiber bronchoscope for sputum suction and alveolar lavage
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional suction catheter
Number of subjects: 106
Study: 27510536

Group type: EXPERIMENTAL
Intervention: Drinking 300 mL H2O during the 4-hour period
Number of subjects: 101

Group type: COMPARATOR
Intervention: No water consumption (Control)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Drinking water
Number of subjects: 101
Study: 23581276

Group type: EXPERIMENTAL
Intervention: Transcranial sonography (TCS) of basal ganglia
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 14
Study: 23175912

Group type: EXPERIMENTAL
Intervention: Dance Movement Therapy (DMT), 2 times a week for 4 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (educational sessions), 2 times a week for 4 weeks
Number of subjects: 50
Study: 20631559

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic agents (especially clozapine) in patients with comorbid psychosis (DD)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic agents in patients without comorbid psychosis (SD)
Number of subjects: 43
Study: 18202708

Group type: EXPERIMENTAL
Intervention: Dorzolamide 2% monotherapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Timolol 0.50% monotherapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination
Number of subjects: 28
Study: 15669934

Group type: EXPERIMENTAL
Intervention: Nursing care based on active involvement of patients in their nutritional care
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 253
Study: 12923369

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 60

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 60
Study: 10344454

Group type: EXPERIMENTAL
Intervention: 400 mg day(‐1) vitamin E supplementation for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no vitamin E supplementation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise (exhaustive exercise including concentric‐eccentric contractions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 0
Study: 8949977

Group type: EXPERIMENTAL
Intervention: Dietary and exercise intervention for one year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary and exercise intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle changes
Number of subjects: 0
Study: 1845591

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31024092

Group type: EXPERIMENTAL
Intervention: High dairy condition (four daily servings of whole milk or full-fat dairy products)
Number of subjects: 60
Study: 30830076

Group type: EXPERIMENTAL
Intervention: 0.15% hyaluronic acid
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Tear substitute with antioxidant properties (Artelac Rebalance drops)
Number of subjects: 43

Group type: COMPARATOR
Intervention: 0.05% Cyclosporin A (CyA) 2 times a day
Number of subjects: 43
Study: 28118425

Group type: EXPERIMENTAL
Intervention: Glutamate injections
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lidocaine injections
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isotonic saline injections
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2 kg pressure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glutamate injections with 0.5 kg and 1.0 kg pressure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: COG coordinates
Number of subjects: 20
Study: 25501607

Group type: EXPERIMENTAL
Intervention: Lipid-based nutritional supplements with added vitamins and minerals (LNS-VM)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Lipid-based nutritional supplements without added vitamins and minerals (LNS)
Number of subjects: 813
Study: 24602760

Group type: EXPERIMENTAL
Intervention: Maintenance rituximab (rituximab 375 mg/m² weekly for 4 weeks followed by 12 infusions at 2-month intervals for 2 years)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Rituximab induction (rituximab 375 mg/m² weekly for 4 weeks)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Maintenance rituximab
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Rituximab induction
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Rituximab groups (both induction and maintenance)
Number of subjects: 379
Study: 23079877

Group type: EXPERIMENTAL
Intervention: Long leg cast with knee flexed 10° and encouraged to bear weight as tolerated
Number of subjects: 81

Group type: COMPARATOR
Intervention: Long leg cast with knee flexed 60° and instructed not to bear weight
Number of subjects: 81
Study: 19774308

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A mixed with 2 ml saline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A mixed with 8 ml saline
Number of subjects: 0
Study: 17324975

Group type: EXPERIMENTAL
Intervention: Installation of a standard retrofit insulation package
Number of subjects: 4407
Study: 14684396

Group type: EXPERIMENTAL
Intervention: Plasma lycopene (increasing quartiles)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Plasma carotenoids (individual addition)
Number of subjects: 483
Study: 11277343

Group type: EXPERIMENTAL
Intervention: Hairgain (active preparation)
Number of subjects: 60
Study: 9533060

Group type: COMPARATOR
Intervention: Eprosartan 400 mg alone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Eprosartan 400 mg with ranitidine 150 mg after 3 days of ranitidine 150 mg twice daily
Number of subjects: 17
Study: 8029793

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - ardeparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - 4 different LMWHs
Number of subjects: 0